Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...

The exon-skipping drug was approved by the FDA for DMD patients with mutations in the dystrophin gene amenable to exon 53 skipping, a group that accounts for around 8% of the total DMD population.

Sarepta's exon-skipping therapies for DMD – Exondys 51, Vyondys 53 (golodirsen), and Amondys 45 (casimersen) – have been the main drivers of Sarepta's revenue growth in recent years ...

a treatment for Duchenne muscular dystrophy or DMD in patients with exon 44 skipping amenable mutations. The company announced it has received authorization from the United Kingdom's Medicines and ...